AG00I8F4

443913-73-3 | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

AG00I8F4

SDS

COA

TIP This product is typically in stock.Please contact us for quotation.

Request For Quotation

• mg
• g
• kg
• ml
• L

No data

• mg
• g
• kg
• ml
• L

No data

No data

Inquire

CAS Number	443913-73-3
Catalog Number	AG00I8F4(AGN-PC-0WAFGR)
Chemical Name	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
IUPAC Name	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
InChI	InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChI Key	UHTHHESEBZOYNR-UHFFFAOYSA-N
MDL Number	MFCD07772346
Molecular Formula	C22H24BrFN4O2
Molecular Weight	475.3540
SMILES	CN1CCC(COC2=CC3=NC=NC(NC4=CC=C(Br)C=C4F)=C3C=C2OC)CC1
UNII	YO460OQ37K
Synonyms	caprelsa, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, vandetanib, Zactima, ZD 6474, ZD-6474, ZD6474, Vandetanib, 443913-73-3, Zactima, ZD6474, Caprelsa, vandetanib (zd6474), N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, ZD 6474, ZD-6474, UNII-YO460OQ37K, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, C22H24BrFN4O2, CHEMBL24828, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, YO460OQ37K, CHEBI:49960, GNF-PF-2188, NCGC00167513-01, 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline, DSSTox_CID_26681, DSSTox_RID_81816, DSSTox_GSID_46681, Vandetanib [INN], N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine, (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine, 4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE, 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-, CAS-443913-73-3, Vandetinib, Vandetanib, Zactima, ZD6474, HSDB 8198, 2ivu, Vandetanib [USAN:INN:BAN:JAN], Caprelsa (TN), AZD-6474, CH 331, Vandetanib (Zactima), AC1MIWRU, DMPC Cyclic Urea 1, Kinome_3316, PubChem22460, BDBM21, SCHEMBL9044, MLS006011672, Vandetanib (JAN/USAN/INN), F9995-0087, GTPL5717, QCR-37, Vandetanib(Zactima),ZD6474/, DTXSID1046681, cid_3081361, CTK8B9016, EX-A422, SYN1090, UHTHHESEBZOYNR-UHFFFAOYSA-N, BCPP000023, HMS3244K03, HMS3244K04, HMS3244L03, HMS3654E11, ZD-64, AOB87780, BCP01925, Tox21_112511, ABP000873, ANW-61824, MFCD07772346, NSC744325, NSC760766, RS0036, s1046, ZINC53683345, AKOS015902350, Tox21_112511_1, AC-5251, AN-3469, CS-0130, DB05294, MCULE-4705827953, NSC-744325, NSC-760766, SB16919, 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, NCGC00167513-02, NCGC00167513-03, NCGC00167513-04, NCGC00167513-09, 338992-00-0, AJ-45811, AK106976, AS-11067, BC224441, EN002713, HY-10260, SC-23330, SMR002530472, AB0008635, AB1008463, LS-184394, RT-016214, ST2407381, FT-0656736, SW218092-2, EC-000.2359, A25648, D06407, V-9402, W-5356, 68541-EP2298768A1, 68541-EP2308855A1, AB01273969-01, AB01273969-02, AB01273969_04, 913V733, SR-00000000462, I14-1942, SR-00000000462-2, BRD-K77625799-001-01-0, 4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline, 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline, 4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline, N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine, 6-[(4R,5S,6S,7R)-4,7-dibenzyl-3-(5-carboxypentyl)-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl]hexanoic acid, Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine, Zactima, ZD6474, Vandetanib (JAN/INN), Microcrystalline cellulose, Vandetanib [USAN:INN], D0G6QF, cc-112, Vandetanib (Pan-TK inhibitor), CH-331, C22-H24-Br-F-N4-O2, ACN-040201, CID3081361, A8555, A10963, C452423, 288383-20-0, ZD6,

Complexity	539
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	474.107g/mol
Formal Charge	0
Heavy Atom Count	30
Hydrogen Bond Acceptor Count	7
Hydrogen Bond Donor Count	1
Isotope Atom Count	0
Molecular Weight	475.362g/mol
Monoisotopic Mass	474.107g/mol
Rotatable Bond Count	6
Topological Polar Surface Area	59.5A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	4.9

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number